期刊
MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 43, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2020.102158
关键词
Disease modifying therapies; Injectable DMTs; Multiple sclerosis; Switching; Teriflunomide
资金
- Sanofi
Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly reduce relapse rates, slow disability worsening, and modify the overall disease course of MS. Decision-making when initiating a DMT should be shared between the patient and physician. Important factors such as prognostic indicators, safety, patient preferences, adherence, and convenience should also be considered. Treatment guidelines recommend switching a DMT when a patient experiences breakthrough disease activity, but also for patients who experience adverse events. Compared with injectable therapies, oral DMTs are often associated with increased treatment adherence and patient satisfaction, due to a less burdensome route of administration and greater tolerability. This review will summarize the available scientific evidence for injectable DMTs and the oral DMT teriflunomide, including considerations for both treatment-naive patients initiating a DMT and patients switching from an injectable DMT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据